Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.43 |
| ▸ | CNR1 | P21554 | 7/20 | 0.39 |
| ▸ | RORC | P51449 | 7/20 | 0.37 |
| ▸ | RORA | P35398 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5771355 | 0.88 | MAPT (0.39) | CNR2CNR1 | |
| SCHEMBL5773239 | 0.85 | MAPT (0.37) | CNR2CNR1RORCRORANR1H4 | |
| SCHEMBL5774525 | 0.83 | MAPT (0.36) | CNR2CNR1RORCRORANR1H4 | |
| SCHEMBL5773308 | 0.83 | MEN1 (0.39) | CNR2CNR1RORCRORANR1H4 | |
| SCHEMBL5772698 | 0.83 | TSHR (0.39) | CNR2CNR1 | |
| SCHEMBL5775864 | 0.82 | SMN1; SMN2 (0.47) | CNR2 | |
| SCHEMBL5771724 | 0.82 | MAPT (0.41) | CNR2HDAC3HDAC1HDAC2 | |
| SCHEMBL5771812 | 0.81 | MAPT (0.38) | CNR2CNR1 | |
| SCHEMBL5777446 | 0.80 | MEN1 (0.41) | HDAC1HDAC2 | |
| SCHEMBL5777020 | 0.80 | MAPT (0.42) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | CNR2 987/4885CNR1 927/4885RORC 620/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | CNR2 848/4885CNR1 502/4885RORC 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.